Koshino, Akihiko
Neuen, Brendon L.
Jongs, Niels
Pollock, Carol
Greasley, Peter J.
Andersson, Eva-Marie
Hammarstedt, Ann
Karlsson, Cecilia
Langkilde, Anna Maria
Wada, Takashi
Heerspink, Hiddo J.L.
Funding for this research was provided by:
The Netherlands Organisation for Scientific Research (VIDI (917.15.306))
Article History
Received: 19 August 2023
Accepted: 12 October 2023
First Online: 28 November 2023
Declarations
:
: Local ethics committees approved all study procedures for the DELIGHT trial and subsequent analyses. Consent was obtained from all study participants.
: Not applicable.
: A. Koshino, N. Jongs and T. Wada have no conflicts of interest.B.L. Neuen has received fees for advisory boards, scientific presentations, speaker fees, steering committee roles and travel support from the American Diabetes Association, AstraZeneca, Bayer, Boehringer and Ingelheim, Cambridge Healthcare Research, Janssen and Medscape, with all honoraria paid to his institution. C. Pollock has served on the steering committee for CREDENCE trial of canagliflozin (sponsored by Janssen Cilag) and is an advisory board member and speaker for Astra Zeneca, and a speaker for Eli Lilly and Boehringer Ingelheim. P.J. Greasley, E.-M. Anderson, A. Hammarstedt, C. Karlsson and A.M. Langkilde are employees and shareholder of AstraZeneca.H.J.L. Heerspink is supported by a VIDI (917.15.306) grant from the Netherlands Organisation for Scientific Research and has served as a consultant for AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Pharma, Fresenius, Gilead, Janssen, Merck, Mundipharma, Mitsubishi Tanabe, and Retrophin; and has received grant support from AbbVie, AstraZeneca, Boehringer Ingelheim, and Janssen.